Status:
COMPLETED
Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
Lead Sponsor:
Novartis
Conditions:
Osteoarthritis, Hip
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. Both ...
Eligibility Criteria
Inclusion
- Diagnosis of primary hip osteoarthritis
- Qualifying pain intensity in the hip joint
- Requiring NSAID therapy
Exclusion
- Rheumatoid arthritis or other inflammatory joint disease
- Disease or disorder that may interfere with pain assessment of the hip
- Open knee/hip surgery within the last year
- Past history of heart attack, stroke or angina (chest pain)
- Liver disorder
- History of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00154219
Start Date
November 1 2004
Last Update
May 21 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
For US Site Information, contact Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Various Sites
Multiple Cities, Canada
3
Various Sites
Multiple Cities, Germany
4
Various Sites
Multiple Cities, Italy